

# Research Article

## Pulmonary cavitation – an under-recognized late complication of severe COVID-19 lung disease

Zaid Zoumot<sup>1</sup>, MBBS; Maria-Fernanda Bonilla<sup>2</sup>, MD; Ali S. Wahla<sup>1</sup>, MBBS; Irfan Shafiq<sup>1</sup>, MBBS; Mateen Uzbek<sup>1</sup>, MBBS; Rania M. El-Lababidi<sup>3</sup>, Pharm.D.; Fadi Hamed<sup>4</sup>, MD; Mohamed Abuzakouk<sup>5</sup>, MBBCh; Mahmoud ElKaissi<sup>6</sup>, MD

<sup>1</sup>Department of Pulmonology, Respiratory Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

<sup>2</sup>Department of Infectious Diseases, Medical Specialties Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

<sup>3</sup>Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, United Arab Emirates

<sup>4</sup>Critical Care Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

<sup>5</sup>Department of Allergy and Immunology, Respiratory Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

<sup>6</sup>Imaging Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

Short Title: **Pulmonary Cavitation in COVID-19 Disease**

### Corresponding author:

Zaid Zoumot, MBBS, PhD, FRCP

Department of Pulmonology, Respiratory Institute, Cleveland Clinic Abu Dhabi, P.O.Box 112412, Abu Dhabi, United Arab Emirates

Telephone: +971 2 501 9000 Ext 46436

Email: [zzoumot@doctors.org.uk](mailto:zzoumot@doctors.org.uk)

**Number of Tables:** 2

**Number of Figures:** 2

**Word Count:** 1795 (Abstract 183, Manuscript 1612)

**Keywords:** COVID-19, SARS-CoV-2, cavity, pulmonary cavitation

## ABSTRACT

**Background:** Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, lung cavitation has not been described in these patients.

**Objectives:** To assess the incidence of pulmonary cavitation and describe its characteristics and evolution.

**Methods:** A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary cavitation.

**Results:** Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of those with COVID-19 pneumonia, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive.

**Conclusion:** Cavitory lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.

## INTRODUCTION

The novel coronavirus disease 2019 (COVID-19) pandemic has caused over 500,000 recorded deaths worldwide thus far[1]. Infection with the novel severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causes COVID-19 which can lead to pneumonia and severe acute respiratory syndrome. The typical abnormalities seen on computerized tomography (CT) of the chest in patients with COVID-19 lung disease have been well described,[2–5] with a comprehensive review and meta- analysis [6] of 55 studies finding peripheral ground glass opacities in most, consolidation in 44% (95% CI: 1–71%), air bronchograms in 43% (95% CI: 8–80%), linear opacities in 41% (95% CI: 7–65%), crazy-paving pattern in 24% (95% CI: 3–92%) and interlobular septal thickening in 23% (95% CI: 1–80%) of the CT scans reviewed. Notable in this meta-analysis and other studies is the absence of cavitation. Similarly, another meta-analysis of 15 studies including 2451 patients did not report any cavitation, but commented on the development of traction bronchiectasis, consolidation, lymphadenopathy and pleural effusions at late stages of severe disease[7]. Here, we present a series of 12 cases of SARS-CoV2 infection that had developed cavitary lung disease while admitted to our tertiary care hospital for treatment of severe COVID-19.

## MATERIALS AND METHODS

A registry of all patients admitted to our institution with COVID-19, and approved by the institution’s Research Ethics Committee, was retrospectively reviewed. In total 689 patients were admitted between February 23<sup>rd</sup> and July 3<sup>rd</sup> 2020, of whom 330 had asymptomatic or

mild disease, 359 had evidence of pneumonia and 110 were admitted to Intensive Care for treatment of respiratory failure. One hundred and seventy eight patients had CT scans of the chest and all patients who had cavitary lung disease on CT scan were identified. Baseline demographics, comorbidities, symptoms, ventilatory and other Intensive care parameters, microbiology, medications received and hospital outcomes were reviewed. Data was extracted by one of three members of the research team, and verified by a second researcher. All CT scans were reviewed by a single thoracic radiologist and imaging characteristics were noted.

In the absence of approved pharmacologic therapy for COVID-19, the Department of Infectious Diseases and the antimicrobial stewardship program at our institution rapidly developed institutional practice guidelines for COVID-19 based on available in-vitro and clinical studies to aid clinicians with treatment decisions. These guidelines were frequently updated based on emerging data. In the early stages of the pandemic asymptomatic and symptomatic patients were treated with a combination of two or three medications that included hydroxychloroquine, lopinavir-ritonavir and favipiravir, for a duration of 5-10 days. Tocilizumab was recommended for those with evolving cytokine release storm (CRS) based on criteria that encompassed clinical, radiological and laboratory parameters. One dose was initially given and a second dose was optional based on the clinical evolution of the patient. Empiric antibacterial and antifungal treatment was not routinely administered unless there was clinical suspicion for secondary pneumonia. Amoxicillin-clavulanate and piperacillin-tazobactam were the most common antibiotics used for COVID-19 patients.

## RESULTS

Twelve patients with COVID-19 disease developed lung cavitation, comprising 1.7% (n=12/689) of all admissions, 3.3% (n=12/359) of those with COVID-19 pneumonia, and 11% (n=12/110) of those admitted to the ICU. Table 1 describes their baseline characteristics, clinical variables and outcomes. Median (range) age was 47 (37 to 67) years, 50% (n=6/12) had diabetes mellitus, 42% (n=5/12) were hypertensive and one had chronic lung disease in the form of chronic obstructive pulmonary disease (COPD). None had received prior immunosuppression. All 12 were males, required invasive mechanical ventilation, and the median (range) time from symptom onset to invasive mechanical ventilation was 8 (3-15) days. Three were admitted directly via our institution's Emergency Department and intubated within 24 hours, whilst the other nine patients were transferred from other hospitals within 72 hours of intubation. At the time of this data review six of the 12 patients had died, another remains critically ill and unlikely to survive, one is still admitted having been recently decannulated off extra-corporeal membrane oxygenation (ECMO) and had his tracheostomy decannulated, and four have been discharged home.

Most patients had completed a course of Hydroxychloroquine (83 % n=10/12) and antivirals (favipilavir or lopinavir/ritonavir) (92%, n=11/12) in the early stages of their illness. All 12 patients received Tocilizumab as clinical evidence of a CRS became apparent accompanied by deteriorating respiratory status and progressively worsening disease on imaging. Overall, this represented 9% (n=12/133) of patients with COVID-19 who received tocilizumab in our institution.

112

# 113 **Imaging characteristics:**

114 Upon admission all patients had baseline chest X-rays which did not reveal any evidence of  
 115 cavitory disease. The 12 patients had the recognized range of imaging features expected in  
 116 severe COVID-19 lung disease. All had bilateral disease with ground glass opacities  
 117 predominantly in the peripheries some with centrally located opacities, most had consolidation  
 118 and air bronchograms, and roughly half had crazy paving pattern and interlobular septal  
 119 thickening. In 10 patients all five lobes were affected, and in two patients the disease spared  
 120 two lobes. The median (range) number of days between symptom onset and the first CT  
 121 demonstrating cavitation was 36 (21 to 54) days, and between intubation and the first CT  
 122 demonstrating cavitation 28 (13 to 49) days. Table 2 describes the cavities in detail. In short,  
 123 five of the 12 patients had solitary cavities with size ranging between 30 mm to 100 mm in  
 124 diameter. All patients with more than one cavity had bilateral cavitation. The appearances and  
 125 morphology of the cavities amongst the group were similar with to that of pulmonary abscesses  
 126 with thick but smooth walls containing internal debris and air fluid levels. Pulmonary infarcts  
 127 were excluded as the CT studies were performed with IV contrast excluding pulmonary emboli.  
 128 All five lobes contained cavities in a similar proportion, with a predilection for the costophrenic  
 129 angles and the apices.

130

131

132

## DISCUSSION

The development of pulmonary cavitation in patients with severe COVID-19 lung disease treated in our institution's ICU was not a rare event (11%, n=12/110). This subgroup of patients had very severe infection with acute respiratory distress syndrome (ARDS) and required a prolonged ICU stay. Median (range) Sequential Organ Failure Assessment (SOFA) score was 23 (range 16-24) on admission, and all patients were leucopenic. Seven of 12 required renal replacement therapy, four developed venous thromboembolism, three required ECMO with two surviving to successful decannulation, and two had thromboembolic cerebrovascular events.

Cavities tended to form in areas of the lung where ground glass opacities were seen in early stages, morphing into more dense consolidation, later developing necrosis and ultimately cavitating. This is demonstrated for patients 8 and 9 in Figures 1 and 2, respectively. We are unable to speculate as to whether bacterial infection and/or invasive fungal coinfection may have contributed to the development of the cavities, or if the infections were opportunistic. However it is uncommon for viral pneumonias,[8] including those due to the other human coronaviruses SARS-CoV[9] and MERS-CoV,[10] to cause pulmonary cavitation even in severe and advanced viral infection. Furthermore, four of twelve patients who had developed pulmonary cavitation (including two of the survivors) had no microbiological, serological, clinical or distinct radiological characteristics of invasive fungal infection and did not receive treatment for this.

Four patients developed hemoptysis and all had features of suspected invasive aspergillosis.

Hemoptysis appeared to have occurred irrespective of cavity size. Similarly, secondary

pneumothorax also occurred in patients with both larger and smaller cavities.

All patients in this series received tocilizumab, a recombinant humanized monoclonal antibody

directed against both the soluble and membrane-bound forms of the interleukin-6 (IL-6)

receptor, in the early stages of a CRS. Tocilizumab is currently approved by the US Food and

Drug Administration (FDA) for the treatment of severe rheumatoid arthritis, systemic juvenile

idiopathic arthritis, giant cell arteritis, and life-threatening CRS induced by chimeric antigen

receptor T cell therapy[11]. Recently it has been associated with improved survival in patients

with severe COVID-19 pneumonia with evidence of CRS.[12,13] In general tocilizumab is well

tolerated but can induce neutropenia, and an increased risk of developing infections has been

reported.[14,15] Furthermore, it may predispose to a delay in detecting active infection

because of the masking effect of a suppressed C reactive protein (CRP) response. Interestingly,

however, only one of 12 patients in our cohort developed neutropenia during their ICU stay.

All patients in this series also received systemic glucocorticoids, which may have survival

benefit in COVID-19[16], but also suppress the immune system by impairing innate immunity.

In the treatment of patients reported here systemic steroids were administered as part of our

ICU protocol for septic shock, based on the Society of Critical Care Medicine guidelines[17] and

not directly for the treatment of their COVID-19.

The high level of morbidity and mortality in this small case series highlights that cavity

formation probably sits at the severe/end-stage of the radiological COVID-19 spectrum. It is



unclear what the natural history of these cavities will be in survivors. This will be informed by future follow-up interval imaging but it is reasonable to assume that though there may be some of regression in the size of the cavities, there will be an increased risk of pneumothorax, hemoptysis, colonization with bacteria including non-tuberculous mycobacteria, fungi and the development of mycetomas in the future.

## CONCLUSION

This study highlights that pulmonary cavitation in patients with severe COVID-19 lung disease can occur, is associated with secondary complications of hemoptysis and pneumothorax, and confers a poor prognosis. Early cross sectional imaging should be considered if there is suspicion of cavitation on plain radiographs, and a more aggressive investigation and treatment of possible invasive fungal infection undertaken. Further studies are needed to determine whether treatment with tocilizumab, systemic glucocorticoids or a combination of both may increase the risk of developing pulmonary cavitation in patients with COVID-19.

194

## 195 **Statement of Ethics**

196 Our institution's Research Ethics Committee approved this retrospective review of an  
197 authorized registry of all patients admitted with COVID-19.

198

## 199 **Conflict of Interest Statement**

200 The authors have no conflicts of interest to declare.

201

## 202 **Funding Sources**

203 There was no funding for this study.

204

## 205 **Author Contributions**

206 Z.Z. conceived this study, collated data and wrote the first draft of the manuscript and all  
207 authors reviewed and contributed to the writing of subsequent drafts, and approved the final  
208 version. M-F.B., A.S.W., I.S., M.U., and R.M.E assisted in data collection and M.E. performed the  
209 imaging review, data collection and analysis.

210

211

## 212 REFERENCES

- 213 1 World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report –  
214 156. Available from: Available at [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2)  
215 [source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2).
- 216 2 Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 Novel Coronavirus  
217 (2019-nCoV) Pneumonia. *Radiology*. 2020 Feb;295(1):210–7.
- 218 3 Kong W, Agarwal PP. Chest Imaging Appearance of COVID-19 Infection. *Radiol*  
219 *Cardiothorac Imaging*. 2020 Feb;2(1):e200028.
- 220 4 Li X, Zeng X, Liu B, Yu Y. COVID-19 Infection Presenting with CT Halo Sign. *Radiol*  
221 *Cardiothorac Imaging*. 2020 Feb;2(1):e200026.
- 222 5 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019  
223 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *Am J Roentgenol*. 2020  
224 Mar;215(1):87–93.
- 225 6 Zheng Y, Wang L, Ben S. Meta-analysis of chest CT features of patients with COVID-19  
226 pneumonia. *J Med Virol*. n/a(n/a). DOI: 10.1002/jmv.26218
- 227 7 Sun Z, Zhang N, Li Y, Xu X. A systematic review of chest imaging findings in COVID-19.  
228 *Quant Imaging Med Surg*. 2020 Apr;10(5):1058–79.
- 229 8 Koo HJ, Lim S, Choe J, Choi S-H, Sung H, Do K-H. Radiographic and CT Features of Viral  
230 Pneumonia. *RadioGraphics*. 2018 May;38(3):719–39.
- 231 9 Wong KT, Antonio GE, Hui DSC, Lee N, Yuen EHY, Wu A, et al. Severe acute respiratory  
232 syndrome: radiographic appearances and pattern of progression in 138 patients. *Radiology*.  
233 2003 Aug;228(2):401–6.
- 234 10 Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory  
235 syndrome coronavirus (MERS-CoV) infection: chest CT findings. *AJR Am J Roentgenol*. 2014  
236 Oct;203(4):782–7.
- 237 11 Tocilizumab (Actemra) injection, for intravenous or subcutaneous use (Genentech Inc,  
238 San Francisco, CA). Prescribing Information [Internet]. [cited 2020 Jul 6]. Available from:  
239 [https://www.gene.com/download/pdf/actemra\\_prescribing.pdf](https://www.gene.com/download/pdf/actemra_prescribing.pdf)
- 240 12 Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the  
241 treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute  
242 respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev*. 2020  
243 Jul;19(7):102568.

244 13 Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab  
245 in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol*. 2020  
246 Jun;0(0). DOI: 10.1016/S2665-9913(20)30173-9

247 14 Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, et al. Risk of serious  
248 infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a  
249 multidatabase cohort study. *Ann Rheum Dis*. 2019;78(4):456–64.

250 15 Feist E, Burmester G-R. Is tocilizumab in combination with traditional DMARDs safe and  
251 effective for patients with active RA? *Nat Clin Pract Rheumatol*. 2009 Mar;5(3):128–9.

252 16 Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone  
253 in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv*. 2020  
254 Jun;2020.06.22.20137273.

255 17 Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis  
256 Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care*  
257 *Med*. 2017 Mar;45(3):486–552.

258

259

260

261

## TABLE LEGENDS

**Table 1:** Patient characteristics and outcomes of those who developed pulmonary cavitation.

**Table 2:** Characteristics of the pulmonary cavities and related events.

## FIGURE LEGENDS

**Fig. 1:** Axial and coronal CT images at from patient 8 on (A) 5<sup>th</sup> May 2020, (B) 26<sup>th</sup> May 2020, and (C) 6<sup>th</sup> June 2020.

**Fig. 2:** Axial and coronal CT images at from patient 9 on (A) 14<sup>th</sup> May 2020, (B) 8<sup>th</sup> June 2020, and (C) 18<sup>th</sup> June 2020.

**Table 1:** Patient characteristics and outcomes of those who developed pulmonary cavitation.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
Age	54	44	67	49	60	51	42	38	42	50	36	42
BMI	30.9	30.4	31.3	29.2	25.1	29.4	26.3	21.5	30.1	19.8	24	27.7
Comorbidities	DM, HT	HT	DM	DM	COPD	HT	HT		DM, HT	DM	DM	DM
On admission												
Time from symptom onset to intubation (days)	6	12	9	7	5	5	8	15	3	9	10	8
P/F ratio	48.8	41.6	49.7	33.0	46.1	47.0	65.3	41.8	70.5	100.1	109.4	104.5
SOFA score (points)	24	21	24	25	23	23	16	21	25	23	18	17
Neutropenia											Y	
Leucocytes (x10 <sup>9</sup> /L)	0.49	1.35	0.3	2.78	0.6	1.1	1.66	1.03	0.46	2.91	1.62	2.63
During admission												
NM blockade	Y	Y	Y	Y	Y	Y	Y	Y	Y			Y
VTE		DVT and PE				PE	DVT			DVT		
CVA	Y									Y		
CRRT/IHD		Y	Y	Y	Y	Y		Y	Y			Y
ECMO							Y	Y	Y			
Proned	Y	Y	Y	Y	Y	Y		Y	Y	Y		
Tracheostomy	Y		Y	Y	Y	Y	Y	Y	Y			
Days of systemic CS	17	15	19	24	11	14	14	25	18	9	6	5
+ve fungal cultures or serology		Y	Y	Y		Y			Y			
Treated for fungal infection	Y	Y	Y	Y		Y	Y		Y			Y
Duration of hospital stay (days)	37	25	53	33	53	74	56	57	57	56	47	40
Outcome												
	Deceased	Deceased	Deceased	Deceased	Deceased	Deceased	Unlikely to survive	Likely to survive	Discharged home	Discharged home	Discharged home	Discharged home

BMI= Body Mass Index, P/F ratio = PaO<sub>2</sub>/FiO<sub>2</sub>, SOFA = Sequential Organ Failure Assessment, NM = neuromuscular, Y=yes, VTE = venous thromboembolism, DVT= deep vein thrombosis, PE=pulmonary embolus, CVA = cerebrovascular accident, CRRT = continuous renal replacement therapy, IHD = intermittent hemodialysis, ECMO = extracorporeal membrane oxygenation, CS= corticosteroids

**Table 2:** Characteristics of the pulmonary cavities and related events.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
<b>No. of Cavities (n)</b>	1	8	8	3	1	1	2	1	9	3	1	5
<b>Largest Cavity (mm)</b>	50	85	60	30	30	30	70	100	54	52	50	40
<b>Bilateral</b>		Y	Y	Y			Y		Y	Y		Y
<b>Location of Cavities</b>												
<b>No. lobes with cavities (n)</b>	1	5	5	3	1	4	2	1	4	3	1	3
<b>RUL</b>		Y	Y	Y				Y	Y	Y	Y	
<b>RML</b>		Y	Y		Y	Y			Y			
<b>RLL</b>		Y	Y			Y	Y		Y	Y		Y
<b>LUL</b>		Y	Y	Y		Y	Y		Y			Y
<b>LLL</b>	Y	Y	Y	Y		Y				Y		Y
<b>Clinical Events</b>												
<b>Developed Pneumothorax</b>				Y				Y	Y			Y
<b>Developed Hemoptysis</b>			Y				Y		Y			Y
<b>Treated for Invasive fungal infection</b>	Y	Y	Y	Y		Y	Y		Y			Y
<b>Bacterial organisms in Sputum/BAL</b>	<i>K. pneumoniae</i>	<i>ECC</i>	<i>MRSA</i>		<i>S. maltophilia, C. koseri</i>	<i>MSSA, S. maltophilia</i>	<i>S. marcescens, S. maltophilia, ECC</i>	<i>K. pneumoniae</i>	<i>Acinetobacter, MRSA</i>	<i>ESBL K. pneumoniae, MRSA</i>	<i>MRSA</i>	<i>K. pneumoniae</i>

Y= Yes, RUL = Right upper lobe, RML = Right middle lobe, RLL = Right lower lobe, LUL = Left upper lobe, LLL = Left lower lobe, BAL = Bronchoalveolar Lavage, MRSA = Methicillin-resistant Staphylococcus aureus, MSSA = Methicillin-sensitive Staphylococcus aureus, K. pneumoniae = Klebsiella pneumonia, ECC = Enterobacter cloacae complex, S. maltophilia = Stenotrophomonas maltophilia, S. marcescens = Serratia marcescens, ESBL = Extended spectrum beta-lactamase









